Enzymatic synthesis of antibody-human serum albumin conjugate for targeted drug delivery using tyrosinase from Agaricus bisporus

Alexandra Rollett, Barbara Thallinger, Anna Ohradanova-Repic, Christian Machacek, Evelyn Walenta, Artur Cavaco-Paulo, Ruth Birner-Grünberger, Juliane Gertrude Bogner-Strauß, Hannes Stockinger, Georg Gübitz*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Highly specific targeted drug delivery devices can be obtained with antibody-human serum albumin (mAb-HSA) conjugates. However, their conventional production involves several reaction steps including chemical modification and activation of both proteins followed by cross-linking often involving toxic chemicals. Here, we describe the enzymatic synthesis of mAb-HSA conjugates for targeted drug delivery devices using tyrosinase from Agaricus bisporus under mild reaction conditions (pH 6.8, 25 °C). Reaction conditions were optimized by using fluorescence labeled HSA to facilitate SDS-PAGE analysis with fluorescence scanning. Enzymatic cross-linking in the presence of natural low molecular weight phenolic compounds (e.g. caffeic acid) resulted in reaction products in the molecular weight range of ∼216 kDa, corresponding to mAb-HSA conjugates. The composition of the conjugates was confirmed with tryptic digestion followed by LC-MS/MS analysis of the resulting peptide fragments. Successful binding of mAb-HSA conjugates (in contrast to free HSA) to MHC II molecules, located on antigen-presenting cells, was demonstrated by both ELISA and flow cytometry analysis.
Original languageEnglish
Pages (from-to)1460-1467
JournalRSC Advances
Volume3
Issue number5
DOIs
Publication statusPublished - 2013

Fields of Expertise

  • Human- & Biotechnology

Fingerprint

Dive into the research topics of 'Enzymatic synthesis of antibody-human serum albumin conjugate for targeted drug delivery using tyrosinase from Agaricus bisporus'. Together they form a unique fingerprint.

Cite this